Catalog No.: PC-73127Not For Human Use, Lab Use Only.
MYCi975 (NUCC-0200975) is a close analog of MYCi361 with improved therapeutic index, binds to MYC protein with KD of 2.5 uM, disrupts MYC/MAX complex formation.
MYCi975 (NUCC-0200975) is a close analog of MYCi361 with improved therapeutic index, binds to MYC protein with KD of 2.5 uM, disrupts MYC/MAX complex formation.
MYCi975 (8 uM) enhances MYC degradation and phosphorylation on T58 in treated cells, also directly increases GSK3β-mediated MYC pT58 in the in vitro kinase assay at 6 uM.
MYCi975 inhibits MYC-dependent cancer cell viability and suppresses MYC transcriptional activity.
MYCi975 increases tolerability at significantly higher doses.
MYCi975 exhibits excellent pharmacokinetic profiles following p.o., i.p. or i.v. administration.
MYCi975 (100 mg/kg/day) inhibits tumor growth in MycCaP allografts with no changes in body weight.
MYCi975 synergized with Ara-C with no obvious impact in NSG mice bearing MV-411 AML xenografts.
